Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties.

Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC.

Ann Surg Oncol. 2019 Aug 2. doi: 10.1245/s10434-019-07653-9. [Epub ahead of print]


Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.

Keegan TH, Press DJ, Tao L, DeRouen MC, Kurian AW, Clarke CA, Gomez SL.

Breast Cancer Res. 2013;15(5):R95.


Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.

Stokes W, Amini A, Maroni PD, Kessler ER, Stokes C, Cost CR, Greffe BS, Garrington TP, Liu AK, Cost NG.

J Pediatr Urol. 2017 Aug;13(4):386.e1-386.e7. doi: 10.1016/j.jpurol.2016.12.009. Epub 2017 Jan 17.


Occurrence of breast cancer subtypes in adolescent and young adult women.

Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA.

Breast Cancer Res. 2012 Mar 27;14(2):R55.


Breast-conserving therapy for triple-negative breast cancer.

Gangi A, Chung A, Mirocha J, Liou DZ, Leong T, Giuliano AE.

JAMA Surg. 2014 Mar;149(3):252-8. doi: 10.1001/jamasurg.2013.3037.


Breast cancer in adolescents and young adults: a review with a focus on biology.

Tichy JR, Lim E, Anders CK.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1060-9. Review.


Correlates of Triple Negative Breast Cancer and Chemotherapy Patterns in Black and White Women With Breast Cancer.

Sheppard VB, Cavalli LR, Dash C, Kanaan YM, Dilawari AA, Horton S, Makambi KH.

Clin Breast Cancer. 2017 Jun;17(3):232-238. doi: 10.1016/j.clbc.2016.12.006. Epub 2017 Jan 6.


Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.


Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity.

Smith EC, Ziogas A, Anton-Culver H.

JAMA Surg. 2013 Jun;148(6):516-23. doi: 10.1001/jamasurg.2013.1680.


Young and uninsured: Insurance patterns of recently diagnosed adolescent and young adult cancer survivors in the AYA HOPE study.

Parsons HM, Schmidt S, Harlan LC, Kent EE, Lynch CF, Smith AW, Keegan TH; AYA HOPE Collaborative.

Cancer. 2014 Aug 1;120(15):2352-60. doi: 10.1002/cncr.28685. Epub 2014 Jun 4.


A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer.

Derouen MC, Gomez SL, Press DJ, Tao L, Kurian AW, Keegan TH.

J Adolesc Young Adult Oncol. 2013 Sep;2(3):95-103.


Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.

Zhang L, Yu Q, Wu XC, Hsieh MC, Loch M, Chen VW, Fontham E, Ferguson T.

Breast Cancer Res Treat. 2018 May;169(1):175-187. doi: 10.1007/s10549-017-4646-1. Epub 2018 Jan 24.


Clinicopathologic and Racial/Ethnic Differences of Colorectal Cancer Among Adolescents and Young Adults.

Holowatyj AN, Lewis MA, Pannier ST, Kirchhoff AC, Hardikar S, Figueiredo JC, Huang LC, Shibata D, Schmit SL, Ulrich CM.

Clin Transl Gastroenterol. 2019 Jul;10(7):e00059. doi: 10.14309/ctg.0000000000000059.


The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.

Alabdulkareem H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, Moo TA.

Breast J. 2018 Mar;24(2):148-153. doi: 10.1111/tbj.12853. Epub 2017 Jul 14.


Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.

Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU.

Oncologist. 2016 Dec;21(12):1495-1501. Epub 2016 Aug 22.


Comparison of primary and secondary breast cancers in adolescents and young adults.

Sadler C, Goldfarb M.

Cancer. 2015 Apr 15;121(8):1295-302. doi: 10.1002/cncr.29200. Epub 2014 Dec 23.


Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction.

Wu W, Cheng S, Deng H, Wu J, Mao K, Cao M.

Medicine (Baltimore). 2016 Jan;95(3):e2547. doi: 10.1097/MD.0000000000002547.


Surgical Management of Breast Cancer in 2010-2011 SEER Registries by Hormone and HER2 Receptor Status.

Lizarraga I, Schroeder MC, Weigel RJ, Thomas A.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S566-72. doi: 10.1245/s10434-015-4591-3. Epub 2015 May 9.


Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer.

Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH.

J Breast Cancer. 2012 Jun;15(2):197-202. doi: 10.4048/jbc.2012.15.2.197. Epub 2012 Jun 28.

Supplemental Content

Support Center